Responsible by design
Responsible by design
Responsible by design

 

Responsible by design is how SCILEX leads by example. We’re committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most. With a passion for patients and a dedication to innovation, SCILEX is lighting the way forward in pain management.

 
Lighting the way forward
Lighting the way forward
Lighting the way forward

Latest
SCILEX news

FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018

SAN DIEGO, Sept. 12, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced today that SCILEX Pharmaceuticals Inc. (“SCILEX”), a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration (“FDA”) acknowledgement of receipt of its recently resubmitted New Drug Application (“NDA”) for ZTlido™ (lidocaine patch 1.8%) which has been considered a … Continue reading FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido™; PDUFA Date Set For February 28, 2018

 

Re-engineering pain management

At SCILEX, we believe that innovation is the path to improving therapeutic outcomes in pain management. We believe our advances in this area are evidence of our tireless dedication to optimizing the patient experience.

X

Share This Page

XS SM MD LG XL